AOD-9604

Pharmaceutical history and evidence quality

• · Developed by Metabolic Pharmaceuticals (Melbourne, Australia) in the late 1990s. The initial hypothesis was that a C-terminal fragment of hGH retained fat-mobilising activity without the IGF-1-mediated anabolic effects of full-length hGH in rodent models.
• · Rodent studies from the Metabolic Pharmaceuticals group reported lipolytic effects in animal models. These preclinical findings were published in peer-reviewed journals and formed the basis for clinical development.
• · Phase I and Phase II trials (ClinicalTrials.gov) tested oral and intranasal formulations in overweight human subjects. Early Phase II data suggested some signal, but subsequent larger Phase IIb and Phase III trials did not replicate sufficient efficacy.
• · Metabolic Pharmaceuticals discontinued the obesity indication programme. The compound was not submitted for marketing authorisation to the FDA, EMA, or TGA.
• · The compound subsequently appeared in US and Australian compounding clinic menus alongside other peptides. No peer-reviewed human randomised controlled trial data supporting its use in any indication has been published to this editorial date.
• · "HGH fragment 176-191" is an alternative name used by some retailers. The naming discrepancy (176-191 vs 177-191) reflects different conventions for numbering the signal-peptide-cleaved mature hGH sequence.

Evidence quality assessment: the animal literature for lipolytic activity exists and was sufficient to support Phase I and Phase II development. The human RCT programme did not confirm the animal findings at the level required for regulatory approval. Claims circulating in online communities that draw solely on the preclinical data or the early Phase II signal should be read in this context.